Biocryst Pharmaceuticals (BCRX) Net Cash Flow Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.47 Bn | 2.11 Bn | 214.41 Mn | -25.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.93% |
| Mar 31, 2026 | 36.60% |
| Dec 31, 2025 | -29.36% |
| Sep 30, 2025 | 47.95% |
| Jun 30, 2025 | 70.36% |
| Mar 31, 2025 | 26.01% |
| Dec 31, 2024 | -69.57% |
| Sep 30, 2024 | 54.31% |
| Jun 30, 2024 | 29.26% |
| Mar 31, 2024 | 15.75% |
| Dec 31, 2023 | -30.67% |
| Sep 30, 2023 | 27.19% |
| Jun 30, 2023 | -28.41% |
| Mar 31, 2023 | -130.00% |
| Dec 31, 2022 | -11.93% |
| Sep 30, 2022 | -86.77% |
| Jun 30, 2022 | -310.41% |
| Mar 31, 2022 | -142.19% |
| Dec 31, 2021 | 139.69% |
| Sep 30, 2021 | -36.72% |